A needle and the damage done: Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4

James Hilliard, Kirk Lalwani

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This case discusses a pharmacokinetic drug interaction between buprenorphine, ritonavir, and atazanavir. Buprenorphine is a cytochrome P450 3A4 substrate. Ritonavir and atazanavir are both potent 3A4 inhibitors.

Original languageEnglish (US)
Title of host publicationA Case Approach to Perioperative Drug-Drug Interactions
PublisherSpringer New York
Pages245-247
Number of pages3
ISBN (Print)9781461474951, 9781461474944
DOIs
StatePublished - Sep 15 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A needle and the damage done: Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4'. Together they form a unique fingerprint.

  • Cite this

    Hilliard, J., & Lalwani, K. (2015). A needle and the damage done: Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4. In A Case Approach to Perioperative Drug-Drug Interactions (pp. 245-247). Springer New York. https://doi.org/10.1007/978-1-4614-7495-1_50